Recursion Pharmaceuticals (RXRX) Stock Jumps After Acquiring Full Rights to REV102 for Rare Bone Disorder

Recursion Pharmaceuticals (RXRX) Stock Jumps After Acquiring Full Rights to REV102 for Rare Bone Disorder

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) saw its stock surge 19% Monday morning following the announcement of its acquisition of full rights to REV102, a promising oral therapy for the rare bone disorder hypophosphatasia (HPP). The move comes after a definitive agreement was announced on July 8 between Recursion and Rallybio Corporation (NASDAQ:RLYB), under which Recursion will acquire Rallybio’s interest in REV102. The deal is valued at up …